NCT05274204No Longer Available不适用
Expanded Access to CA102N in One Patient Who Completed at Least 12 Cycles of Combination Therapy of CA102N Plus Lonsurf in Clinical Study Number of HS-CA102N-101
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.
详细描述
In the individual patient expanded access, the subject who was enrolled in Phase 1 trial (Study Number: HS-CA102N-101) Part 2 (dose expansion) and had completed at least 12 treatment cycles with CA102N combined with trifluridine /tipiracil (LONSURF) will be provided access to treatment with CA102N (0.72 mg/kg Nimesulide Equivalent of CA102N).
研究设计
- 研究类型
- Expanded Access
入排标准
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
No Longer Available
不适用
Expanded Access to ANG1005 for Individual PatientsAnaplastic AstrocytomaAnaplastic OligodendrogliomaBreast Cancer With Recurrent Brain MetastasesLeptomeningeal CarcinomatosisNCT02755987Angiochem Inc
Unknown
不适用
Individual Patient Expanded Access IND for the Treatment of StrokeStroke, IschemicStrokeNCT04907188Hope Biosciences Research Foundation
撤回
不适用
SINGLE PATIENT EXPANDED ACCESS OF A PROSPECTIVE, MULTICENTER CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND PROBABLE BENEFIT OF THE KERAKLEAR NON-PENETRATING KERATOPROSTHESIS IN SUBJECTS WITH CORNEAL OPACITY WITH POOR PROGNOSIS FOR CORNEAL TRANSPLANTCORNEAL OPACITY WITH POOR PROGNOSIS FOR CORNEAL TRANSPLANTNCT03812341University of California, Irvine
No Longer Available
不适用
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of PembrolizumabNCT04135092National Institutes of Health Clinical Center (CC)
Available
不适用
Expanded Access to Provide Sevabertinib (BAY 2927088) for the Treatment of Locally Advanced or Metastatic NSCLC With HER2 MutationAdvanced Non-small Cell Lung CancerCancerNCT06761976Bayer